Novartis strengthens radioligand therapy pipeline with agreement to buy Mariana Oncology Ruchika Sharma3 May 2024 12:58 PM ISTBasel: Novartis has announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based...
India becoming attractive for clinical trials: Pharma industry leaders Ruchika Sharma29 April 2024 2:33 PM ISTNew Delhi: Experts from the pharmaceutical sector have noted that over the last decade, clinical trials in India have undergone significant...
CDSCO Panel Grants Novartis Protocol Amendment Proposal For Ianalumab Dr. Divya Colin27 April 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis radioligand therapy Lutathera gets USFDA nod for pediatric patients with gastroenteropancreatic neuroendocrine tumors Ruchika Sharma25 April 2024 12:14 PM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Lutathera (USAN: lutetium Lu 177 dotatate / INN:...
Novartis Gets CDSCO Panel Nod to Study anti-cancer drug Ribociclib Dr. Divya Colin21 April 2024 5:30 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Arvinas, Novartis collaborate for development, commercialization of ARV-766 for prostate cancer Ruchika Sharma14 April 2024 10:00 AM ISTNew Haven: Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, has...
Novartis tender offer for MorphoSys AG commences Ruchika Sharma12 April 2024 3:30 PM ISTBasel: Novartis has published the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all...
Novartis Fabhalta gets positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria Ruchika Sharma24 March 2024 2:30 PM ISTBasel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Submit Interim Safety, Efficacy Data: CDSCO Panel Tells Novartis on Crizanlizumab Dr. Divya Colin20 March 2024 6:00 PM ISTNew Delhi: Reviewing the status of the ongoing studies of Crizanlizumab concentrate for solution for infusion 10mg/mL (100mg/10mL), the Subject Expert...
Modify Clinical study protocol of Iptacopan study in aHUS: CDSCO Panel Tell Novartis Dr. Divya Colin17 March 2024 5:15 PM ISTNew Delhi: Reviewing the Phase IIIb clinical trial study protocol of Iptacopan, the Subject Expert Committee (SEC) functional under the Central...
Former Novartis India Chief Ranjit Shahani no more Ruchika Sharma11 March 2024 3:22 PM ISTNew Delhi: Former Vice Chairman and Managing Director of Novartis India and Chairman of JB Pharmaceuticals, Ranjit Shahani has passed...
Britain health regulator revokes conditional marketing authorisation for Novartis sickle cell drug Adakveo Ruchika Sharma22 Feb 2024 11:20 AM ISTSickle cell disease is a genetic disorder in which misshapen blood cells cause strokes, organ damage, severe pain and early death.
